Analyst Reco. Tandem Diabetes Care, Inc.

Equities

TNDM

US8753722037

Real-time Estimate Cboe BZX Other stock markets 15:44:46 01/05/2024 BST			5-day change	1st Jan Change
36.32 ^USD	-1.01%		+3.62%	+23.02%

04-30	North American Morning Briefing : More Earnings -2-	DJ
04-29	Wells Fargo Upgrades Tandem Diabetes Care to Overweight From Equalweight, Price Target is $45	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wells Fargo Upgrades Tandem Diabetes Care to Overweight From Equalweight, Price Target is $45	04-29	MT
Leerink Partners Upgrades Tandem Diabetes Care to Outperform Rating, Price Target is $45	04-25	MT
Stifel Adjusts Price Target on Tandem Diabetes Care to $40 From $37, Maintains Buy Rating	04-23	MT
Stifel Upgrades Tandem Diabetes Care to Buy From Hold, Adjusts Price Target to $37 From $24	03-26	MT
Citigroup Raises Price Target on Tandem Diabetes Care to $31 From $25, Keeps Neutral Rating	03-15	MT
UBS Raises Tandem Diabetes Care Price Target to $28 From $18, Maintains Neutral Rating	01-22	MT
TD Cowen Raises Tandem Diabetes Care Price Target to $35 From $22, Maintains Outperform Rating	01-18	MT
BofA Securities Cuts Price Target on Tandem Diabetes Care to $18 From $33, Keeps Underperform Rating	18/10/23	MT
Citigroup Cuts Tandem Diabetes Care's Price Target to $23 From $31, Keeps Neutral Rating	02/10/23	MT
Jefferies Adjusts Price Target on Tandem Diabetes Care to $45 From $47, Maintains Buy Rating	02/10/23	MT
Citigroup Adjusts Price Target on Tandem Diabetes Care to $31 From $33, Maintains Neutral Rating	21/08/23	MT
Baird Trims Price Target on Tandem Diabetes Care to $32 From $33, Maintains Neutral Rating	21/08/23	MT
UBS Adjusts Tandem Diabetes Care Price Target to $32 From $30, Maintains Neutral Rating	07/08/23	MT
Barclays Adjusts Price Target on Tandem Diabetes Care to $62 From $71, Keeps Overweight Rating	07/08/23	MT
Baird Adjusts Price Target on Tandem Diabetes Care to $33 From $38, Maintains Neutral Rating	04/08/23	MT
Citigroup Downgrades Tandem Diabetes Care to Neutral From Buy, Adjusts Price Target to $33 From $45	04/08/23	MT
UBS Adjusts Tandem Diabetes Care Price Target to $30 From $45, Maintains Neutral Rating	14/06/23	MT
Craig Hallum Adjusts Tandem Diabetes Care Price Target to $50 From $74, Maintains Buy Rating	13/06/23	MT
Citigroup Adjusts Price Target on Tandem Diabetes Care to $45 From $55, Keeps Buy Rating	05/06/23	MT
BofA Securities Downgrades Tandem Diabetes Care to Underperform From Neutral, Adjusts Price Target to $33 From $45	05/05/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Tandem Diabetes Care, Inc.

Equities

TNDM

US8753722037

Analyst Reco.

Filters